Aprea Therapeutics (NASDAQ:APRE – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Aprea Therapeutics to similar companies based on the strength of its valuation, earnings, risk, dividends, analyst recommendations, institutional ownership and profitability.
Institutional & Insider Ownership
34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 10.5% of Aprea Therapeutics shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Aprea Therapeutics and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Aprea Therapeutics | $290,000.00 | -$12.60 million | -0.66 |
| Aprea Therapeutics Competitors | $703.19 million | $8.65 million | -18.47 |
Aprea Therapeutics’ peers have higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Aprea Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aprea Therapeutics | N/A | -44.69% | -39.12% |
| Aprea Therapeutics Competitors | -12,224.75% | -204.85% | -31.52% |
Risk & Volatility
Aprea Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Aprea Therapeutics’ peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Aprea Therapeutics and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aprea Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Aprea Therapeutics Competitors | 9941 | 15335 | 45756 | 1605 | 2.54 |
Aprea Therapeutics currently has a consensus price target of $2.80, indicating a potential upside of 502.28%. As a group, “Biotechnology” companies have a potential upside of 134.59%. Given Aprea Therapeutics’ higher possible upside, equities analysts plainly believe Aprea Therapeutics is more favorable than its peers.
Summary
Aprea Therapeutics peers beat Aprea Therapeutics on 7 of the 13 factors compared.
About Aprea Therapeutics
Aprea Therapeutics is a clinical-stage biotechnology company focused on developing investigational cancer treatments. Its research centers on the DNA damage response, a network of cellular processes that helps repair damaged DNA and that can be targeted in some cancers. The company’s pipeline has included ATR inhibitors, a class of experimental medicines intended to disrupt cancer cells’ ability to respond to DNA damage. Aprea has evaluated these candidates in early-stage clinical research; they are investigational and have not been established as approved treatments.
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
